Saturday 17 October 2026
Export LSDIF’s income statement to Excel — free account
Lucy Scientific Discovery Inc.
LSDIF Healthcare Drug Manufacturers Specialty & Generic
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow LSDIF
| Dec '23 | Sep '23 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | — |
+5 more quarters Free account |
P/S ratio |
0.00 | — | 0.00 | — | |
P/FCF ratio |
0.00 | — | 0.00 | — | |
P/Operating CF |
(6.32) | — | (7.85) | — | |
P/B ratio |
57.59 | — | 3.12 | — | |
Price to Tangible BV |
0.00 | — | 4.57 | — | |
EV/Sales |
0.00 | — | 0.00 | — | |
EV/EBITDA |
0.00 | — | 0.00 | — | |
EV/Operating CF |
(0.99) | — | (3.36) | — | |
EV/FCF |
(0.93) | — | (3.39) | — | |
Quick Ratio |
0.06 | 0.11 | 0.74 | 1.67 | |
Current Ratio |
0.38 | 0.71 | 1.41 | 2.80 | |
Net Debt/EBITDA |
0.24 | 0.15 | 0.69 | 1.43 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.28 | 0.64 | 0.72 | 0.50 | |
Capex/Depreciation |
0.00 | (2.61) | (10.79) | 0.00 | |
Interest Coverage |
(6.71) | (4.12) | (6.08) | (4.46) | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
8,951.55% | 0.00% | 33,847.14% | 0.00% | |
Intangible Assets out of Total Assets |
0.34 | 0.23 | 0.17 | 0.00 | |
Share Based Compensation of Revenue |
185.57% | 0.00% | 1,507.14% | 0.00% | |
Graham Net Nets |
(0.61) | — | (0.02) | — | |
Graham Number |
0.00 | — | 0.00 | — | |
Earnings Yield |
(277.66%) | — | (61.49%) | — | |
Free Cash Flow Yield |
(134.99%) | — | (28.98%) | — | |
Revenue per Share |
0.01 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(0.42) | (0.73) | (1.46) | (1.49) | |
Capex per Share |
0.00 | (0.07) | (0.24) | 0.00 | |
Free Cash Flow per Share |
(0.42) | (0.80) | (1.70) | (1.49) | |
Cash per Share |
0.12 | 0.14 | 1.32 | 2.51 | |
Shareholders Equity per Share |
0.05 | 1.54 | 3.68 | 4.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.05 | 1.54 | 3.68 | 4.37 | |
Free Cash Flow |
(0.74) | (1.41) | (2.16) | (2.03) | |
Working Capital |
(2.15) | (0.64) | 1.11 | 3.73 | |
Capital Expenditures |
0.00 | (0.12) | (0.30) | 0.00 | |
Net Current Asset Value |
(2.87) | (1.98) | (0.28) | 2.36 | |
EV/EBIT |
0.00 | — | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 42.86 | 0.00 | |
Price to Operating Income |
0.00 | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.02 | 0.01 | — | — | |
Average Payables |
2.29 | — | — | — | |
Average Assets |
4.53 | 3.13 | 4.39 | 4.70 | |
Average Common Equity |
(3.35) | (1.52) | — | — |
Columns are period end dates